Treatment with statins in the acute phase of ischemic stroke

References

• Laufs U, Liao JK. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler. Thromb. Vasc. Biol. 23(2), 156–157 (2003).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol. 81, 333–335 (1998).
   PubMed Web of Science ®Google Scholar
• Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99, 216–223 (1999).
   PubMed Web of Science ®Google Scholar
• White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N. Engl. J. Med. 343, 317–326 (2000).
   PubMed Web of Science ®Google Scholar
• Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 106, 1690–1695 (2002).
   PubMed Web of Science ®Google Scholar
• Prospective studies collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346, 1647–1653 (1995).
   PubMedGoogle Scholar
• Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch. Intern. Med. 155, 50–55 (1995).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 348, 1079–1082 (1996).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35(12), 2902–2909 (2004).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363(9411), 757–767 (2004).
   PubMed Web of Science ®Google Scholar
• Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr. Opin. Lipidol. 10, 543–559 (1999).
   PubMed Web of Science ®Google Scholar
• Delgado P, Montaner J, Chacón P et al. Pleiotropic effects of several statins used in secondary prevention of ischemic stroke. Neurología 18, 552 (2003).
   Google Scholar
• Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32, 2575–2579 (2001).
   PubMed Web of Science ®Google Scholar
• Curb JD, Abbott RD, Rodriguez BL et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 107, 2016–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103, 1933–1935 (2001).
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159, 27–33 (2001).
   PubMedGoogle Scholar
• Manoonkitiwongsa PS, Jackson-Friedman C, McMillan PJ, Schultz RL, Lyden PD. Angiogenesis after stroke is correlated with increased numbers of macrophages: the clean-up hypothesis. J. Cereb. Blood Flow Metab. 21, 1223–1231 (2001).
   PubMed Web of Science ®Google Scholar
• Wei L, Erinjeri JP, Rovainen CM, Woolsey TA. Collateral growth and angiogenesis around cortical stroke. Stroke 32, 2179–2184 (2001).
   PubMed Web of Science ®Google Scholar
• Mofidi R, Crotty TB, McCarthy P, Sheehan SJ, Mehigan D, Keaveny TV. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br. J. Surg. 88, 945–950 (2001).
   PubMed Web of Science ®Google Scholar
• Vincent L, Chen W, Hong L et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 495, 159–166 (2001).
   PubMed Web of Science ®Google Scholar
• Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 105, 739–745 (2002).
   PubMed Web of Science ®Google Scholar
• Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103, 926–933 (2001).
   Google Scholar
• Amarenco P, Bogousslavsky J, Callahan AS et al. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 16(4), 389–395 (2003).
   PubMed Web of Science ®Google Scholar
• Lalouschek W, Lang W, Greisenegger S, Mullner M, Vienna Stroke Study Group. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 34(1), 105–110 (2003).
   PubMed Web of Science ®Google Scholar
• Delgado P, Montaner J, Molina C, Alvarez-Sabín J. Lipids profile in the hyperacute phase of stroke. Med. Clin. (Barc.) (2004) (In Press).
   PubMedGoogle Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285(13), 1711–1718 (2001).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 292(11), 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30, 1969–1973 (1999).
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U. Effects of statins on endothelium and signalling mechanisms. Stroke 35(Suppl. I), 2708–2711 (2004).
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21(11), 1712–17129 (2001).
   PubMed Web of Science ®Google Scholar
• Montaner J, Rovira A, Molina CA et al. Plasmatic level of neuroinflammatory markers (matrix metalloproteinase-9) predict the extent of diffusion-weighted image lesion in hyperacute stroke. J. Cereb. Blood Flow Metab. 23, 1403–1407 (2003).
   PubMed Web of Science ®Google Scholar
• Montaner J, Alvarez-Sabín J, Molina C et al. Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32, 2762–2767 (2001).
   PubMed Web of Science ®Google Scholar
• Montaner J, Molina CA, Monasterio J et al. Matrix metalloproteinase (MMP-9) pre-treatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107, 598–603 (2003).
   PubMed Web of Science ®Google Scholar
• Laufs U, La FV, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97, 1129–1135 (1998).
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 95, 8880–8885 (1998).
   PubMed Web of Science ®Google Scholar
• Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101, 2711–2719 (1998).
   PubMedGoogle Scholar
• Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med. 6, 1004–1010 (2000).
   PubMed Web of Science ®Google Scholar
• Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266–24271 (1998).
   PubMed Web of Science ®Google Scholar
• Laufs U, Endres M, Stagliano NE et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 106, 15–24 (2000).
   PubMed Web of Science ®Google Scholar
• Laufs U, Gertz K, Huang P et al. Atorvastatin upregulates Type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31(10), 2442–2449 (2000).
   PubMed Web of Science ®Google Scholar
• Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32(4), 980–986 (2001).
   PubMed Web of Science ®Google Scholar
• Sterzer P, Meintzschel F, Rosler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 32(12), 2817–2820 (2001).
   PubMed Web of Science ®Google Scholar
• Daimon M, Aomi S, Kawamata T, Kurosawa H. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces delayed neuronal death following transient forebrain ischemia in the adult rat hippocampus. Neurosci Lett. 362(2), 122–126 (2004).
   PubMedGoogle Scholar
• Sironi L, Cimino M, Guerrini U et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler. Thromb. Vasc. Biol. 23, 322–327 (2003).
   PubMed Web of Science ®Google Scholar
• Kawashima S, Yamashita T, Miwa Y et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 34, 157–163 (2003).
   PubMed Web of Science ®Google Scholar
• Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 32, 1112–1115 (2001).
   PubMed Web of Science ®Google Scholar
• Yoon SS, Dambrosia J, Chalela J et al. Rising statin use and effect on ischemic stroke outcome. BMC Med. 2(1), 4 (2004).
   PubMed Web of Science ®Google Scholar
• Martí-Fábregas J, Gomis M, Arboix A et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35, 1117–1123 (2004).
   PubMed Web of Science ®Google Scholar
• Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J. Neurol. Sci. 221, 5–10 (2004).
   PubMedGoogle Scholar
• Bushnell CD, Newby LK, Goldstein LB, Lin F, Yaffe K, Simon JA. Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS). Neurology. 62(6), 968–970 (2004).
   PubMedGoogle Scholar
• Moonis M, Goldstein LB, Sandage BW, Schwiderski U, Fisher M. Post-stroke statins improve outcome after acute ischemic stroke. Neurology 60(Suppl. 1), A327 (2003).
   Google Scholar
• Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279, 1643–1650 (1998).
   PubMed Web of Science ®Google Scholar
• Laufs U, Endres M, Custodis F et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102, 3104–3110 (2000).
   PubMed Web of Science ®Google Scholar
• Gertz K, Laufs U, Lindauer U et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34, 551–557 (2003).
   PubMed Web of Science ®Google Scholar
• Pucetti L, Pasqui AL, Pastorelli M et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost. 90, 476–482 (2003).
   PubMedGoogle Scholar
• Spencer FA, Fonarow GC, Frederick P et al. Does early withdrawal of statin therapy in patients with acute coronary syndromes increase hospital morbidity and mortality? Circulation 106(Suppl. II), 493 (2002).
   Google Scholar
• Montaner J, Chacón P, Krupinski J et al. Safety and efficacy of statins in the acute phase of ischemic stroke: the MISTICS trial. Stroke 35, 293 (2004).
   Google Scholar
• Montaner J, Chacón P, Krupinski J et al. Safety and efficacy of statins in the acute phase of ischemic stroke: the MISTICS Trial. Cerebrovasc. Dis. 17(Suppl. 5), 29 (2004).
   Google Scholar
• Jung KH, Chu K, Jeong SW et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 35, 1744–1749 (2004).
   PubMed Web of Science ®Google Scholar
• Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J. Neurosurg. 101, 104–107 (2004).
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer’s disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439–1443 (2000).
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356, 1627–1631 (2000).
   PubMed Web of Science ®Google Scholar